Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Current Assets (2020 - 2025)

Pulse Biosciences has reported Current Assets over the past 6 years, most recently at $97.2 million for Q3 2025.

  • Quarterly results put Current Assets at $97.2 million for Q3 2025, up 20.82% from a year ago — trailing twelve months through Sep 2025 was $97.2 million (up 20.82% YoY), and the annual figure for FY2024 was $119.4 million, up 163.52%.
  • Current Assets for Q3 2025 was $97.2 million at Pulse Biosciences, down from $108.2 million in the prior quarter.
  • Over the last five years, Current Assets for PLSE hit a ceiling of $120.9 million in Q1 2025 and a floor of $22.2 million in Q1 2022.
  • Median Current Assets over the past 5 years was $60.0 million (2023), compared with a mean of $63.1 million.
  • Biggest five-year swings in Current Assets: crashed 64.24% in 2022 and later skyrocketed 297.08% in 2025.
  • Pulse Biosciences' Current Assets stood at $45.3 million in 2021, then surged by 37.11% to $62.1 million in 2022, then decreased by 27.06% to $45.3 million in 2023, then skyrocketed by 163.52% to $119.4 million in 2024, then decreased by 18.66% to $97.2 million in 2025.
  • The last three reported values for Current Assets were $97.2 million (Q3 2025), $108.2 million (Q2 2025), and $120.9 million (Q1 2025) per Business Quant data.